(Q37610628)

21 August 2017

1 reference

title

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours (English)

1 reference

21 August 2017

0 references

1 reference

5

1 reference

21 August 2017

Ester Fonsatti

1

1 reference

21 August 2017

Hugues J M Nicolay

series ordinal

2

1 reference

21 August 2017

Maresa Altomonte

series ordinal

3

1 reference

21 August 2017

Alessia Covre

series ordinal

4

1 reference

21 August 2017

publication date

7 October 2009

1 reference

21 August 2017

published in

Cardiovascular Research

1 reference

21 August 2017

volume

86

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

12-19

1 reference

Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin in angiogenesis and vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Novel biochemical pathways of endoglin in vascular cell physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Zona pellucida domain proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Assignment of the human endoglin gene (END) to 9q34-->qter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Vascular gene transfer driven by endoglin and ICAM-2 endothelial-specific promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Characterization of murine S-endoglin isoform and its effects on tumor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin (CD105) expression in the human heart throughout gestation: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Defective angiogenesis in mice lacking endoglin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin (CD105): a marker of tumor vasculature and potential target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

TGF-beta signaling in vascular biology and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin modulates cellular responses to TGF-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

CD105 prevents apoptosis in hypoxic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin regulates nitric oxide-dependent vasodilatation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Hereditary hemorrhagic telangiectasia: an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin has a crucial role in blood cell-mediated vascular repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Endothelial proliferation in tumours and normal tissues: Continuous labelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Targeting vascular endothelium with avidin microbubbles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Production and characterization of a high-affinity nanobody against human endoglin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

CD105 is important for angiogenesis: evidence and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Lack of specificity of endoglin expression for tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Antibody-directed targeting of the vasculature of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

Is it the primetime for endoglin (CD105) in the clinical setting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP332

21 January 2018

Identifiers

DOI

10.1093/CVR/CVP332

1 reference

21 August 2017

1 reference